Francesco Bellinato, Paolo Gisondi, Giampiero Girolomoni
Issues - Febbraio 2022
Francesco Bellinato, Paolo Gisondi, Giampiero Girolomoni
Nina Magnolo, Külli Kingo, Vivian Laquer, John Browning, Adam Reich, Jacek C Szepietowski, Deborah Keefe, Rafal Mazur, Prayashi Ghelani, Pascal Forrer, LindaAnn Wraith, Manmath Patekar
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
J Am Acad Dermatol. 2022 Jan;86(1):122-130Stefano Piaserico, Paolo Gisondi, Simone Cazzaniga, Sara Di Leo, Luigi Naldi
Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence
J Invest Dermatol. 2022 Feb;142(2):355-363L Penso, R Dray-Spira, A Weill, M Zureik, E Sbidian
Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France
Br J Dermatol. 2022 Jan;186(1):59-68April W Armstrong, Ahmed M Soliman, Keith A Betts, Yan Wang, Yawen Gao, Vassilis Stakias, Luis Puig
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
Dermatol Ther (Heidelb). 2022 Jan;12(1):167-184Curdin Conrad, Christine-Elke Ortmann, Marc Vandemeulebroecke, Torben Kasparek, Kristian Reich
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis
Dermatol Ther (Heidelb). 2022 Jan;12(1):233-241Linda Stein Gold, Kim Papp, David Pariser, Lawrence Green, Neal Bhatia, Howard Sofen, Lorne Albrecht, Melinda Gooderham, Mindy Chen, Maria Paris, Yao Wang, Kristina Callis Duffin
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
J Am Acad Dermatol. 2022 Jan;86(1):77-85James G Krueger, Iain B McInnes, Andrew Blauvelt
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
J Am Acad Dermatol. 2022 Jan;86(1):148-157A Pinter, L J Green, J Selmer, M Praestegaard, L S Gold, M Augustin, trial investigator group
A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):228-236K Hansel, A Zangrilli, L Bianchi, K Peris, A Chiricozzi, A Offidani, F Diotallevi, M C Fargnoli, M Esposito, P Amerio, G Gualdi, L Bianchi, L Stingeni
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e111-e113Deepak M W Balak, Stefano Piaserico, Ismail Kasujee
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies
Psoriasis (Auckl). 2021 Dec 7;11:151-168A Al-Janabi, Z Z N Yiu
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Psoriasis (Auckl). 2022 Jan 6;12:1-14D Thaçi, K Eyerich, A Pinter, M Sebastian, K Unnebrink, S Rubant, D A Williams, P Weisenseel
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial
Br J Dermatol. 2022 Jan;186(1):30-39Mark Lebwohl, Richard G Langley, Carle Paul, Lluis Puíg, Kristian Reich, Peter van de Kerkhof, Hsiuan-Lin Wu, Sven Richter, Shauna Jardon, Paolo Gisondi
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
Dermatol Ther (Heidelb). 2022 Jan;12(1):61-78Shinichi Imafuku, Yayoi Tada, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa
Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
Dermatol Ther (Heidelb). 2022 Jan;12(1):121-135Y Lytvyn, J R Georgakopoulos, A Mufti, A R Devani, M J Gooderham, V Jain, P Lansang, R Vender, V H Prajapati, J Yeung